Knight Therapeutics Inc. (KHTRF)

Market Cap	444.77M
Revenue (ttm)	259.35M
Net Income (ttm)	7.70M
Shares Out	n/a
EPS (ttm)	0.07
PE Ratio	57.79
Forward PE	93.04
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	2,467
Open	4.494
Previous Close	4.448
Day's Range	4.440 - 4.494
52-Week Range	3.480 - 4.550
Beta	0.15
RSI	68.74
Earnings Date	Aug 7, 2025

About Knight Therapeutics

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 745
• Stock Exchange: OTCMKTS
• Ticker Symbol: KHTRF

Financial Performance

Financial numbers in CAD